Humacyte
Biotechnology Research • 
Durham, North Carolina, United States • 101-200 Employees
Company overview
| Headquarters | 2525 E NC Highway 54, 2525 E Hwy 54, Durham, NC 27713, US |
| Phone number | +19193139633 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Biotechnology, Regenerative Medicine, Bioengineering |
| Founded | 2004 |
| Employees | 101-200 |
| Socials |
Key Contacts at Humacyte
Tony Mattair
Senior Director, Sales Training & Development
Rhianna Jobe
Senior Director, Commercial Operations
Charles Bruce Green
Member Board Of Directors
Vincent Mazzurco
Director Of Sales
Warren Prosser
Executive Director, Clinical Operations
Colleen Conway
Director, Cmc Regulatory Affairs
Kellie Hamilton
Director, Clinical Data Management
Gerry Glennon
Executive Director, Supply Chain
David Laudeman
Associate Director Cqv
Manisha Patel
Director, Safety And Pharmacovigilance
Humacyte Email Formats
Humacyte uses 5 email formats. The most common is {first name}{last name} (e.g., johndoe@humacyte.com), used 34% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@humacyte.com | 34% |
{first initial}{last name} | jdoe@humacyte.com | 30.8% |
{last name} | doe@humacyte.com | 29.5% |
{first initial}.{last name} | j.doe@humacyte.com | 1.9% |
{last name}{last name} | doedoe@humacyte.com | 1.9% |
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is proud to announce that in Dec 2024, FDA granted full approval for our Acellular Tissue Engineered Vessel (ATEV), a first-in-class, universally implantable, bioengineered human vessel for extremity arterial trauma. This approval is a significant milestone in regenerative medicine, offering a new treatment option for patients with severe arterial injuries.See the Prescribing Information, including Boxed Warning: https://bit.ly/4dl5tuL This is the first approval in our bioengineered ATEV Platform where we are continuing to investigate use of our lab-grown tissues and organs to improve the lives of patients and transform the practice of medicine. We develop and manufacture acellular tissues that are meant to be universally implantable and remodel with the patient's own cells over time. The goal is to grow spare parts for people. Humacyte’s ATEV is in clinical trials for arteriovenous access for hemodialysis, and peripheral arterial disease. Investigational preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s ATEV for performing hemodialysis in AV Access was the first indication to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the ATEV technology received priority designation for the treatment of extremity arterial repair by the U.S. Secretary of Defense prior to its FDA approval in Dec 2024 for that purpose. For more information, visit https://Humacyte.com.
Humacyte revenue & valuation
| Annual revenue | $818,000 |
| Revenue per employee | $5,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $2,700,000 |
| Total funding | $280,200,000 |
Employees by Management Level
Total employees: 101-200
Seniority
Employees
Employees by Department
Humacyte has 106 employees across 14 departments.
Departments
Number of employees
Funding Data
Explore Humacyte's funding history, including investment rounds, total capital raised, and key backers.
Humacyte Tech Stack
Discover the technologies and tools that power Humacyte's digital infrastructure, from frameworks to analytics platforms.
UI frameworks
Miscellaneous
JavaScript libraries
Miscellaneous
JavaScript frameworks
Font scripts
Programming languages
Blogs
Analytics
SEO
Font scripts
India
Australia
Germany
Netherlands
Frequently asked questions
4.8
40,000 users
